Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chartman, be nice. Kyza - take a loss? You kidding? This is one of the best lotto tickets around. There's no technical indicator you can use to analyze this chart, other than that it's sitting at a bottom. Look at a weekly again. Also, there is a catalyst coming up, which I confirmed in the link I posted regarding the Gendicine patent.
Now if you own too much of it I'd maybe consider taking some off the table, but you're supposed to slowly buy into these things.
At the moment, I have about $400 in it, which is small. If it starts heading towards .10 and gets decent volume, I'll consider adding another $200, and another on a confirmed breakout.
Please keep trying, I don't want you making a nickel here...eom
I will gladly take the loss to get out of this pos.
But I will never get filled.
Not for another 2 years.
Any news due out in the next week or so on this?
Sure hope we start getting some volume soon.
I dont think you'll ever really get a successful pump on this thing without there being a real catalyst. Sure, it's undervalued, but at this point, nobody really cares. I think some news will come out within the next 6months, so I'm going to sit on what I have and buy more at .01, maybe .02. I'm not putting more than $500 in this trade, because 1) I'm smarter than that, and 2)if I slowly accumulate lower, it'll be easy to get out mid range if I need to.
shortterm...eom
When? In years from now? If we close below 04 it wouldn't be good.
Yep..this will be a great play..eom
You are satisfied with your .05 right now?
lol that unfortunately wasn't me, I'm at the ask,now
Yes!! now we can start moving up, KYZA is out!!!eom
Since last msg
hOW LONG YOU BEEN THERE
lol I'll buy at .02...My .055 avg is a little unsafe.
I'll provide you with the liquidity you need ...sell to me at .02.
lol you waste your time.
Just sell at the bid your negativity is becoming annoying..man I hate newbie traders...eom
Been trying to get out at ask all day.
yea it's full just no action.....04 x .05 2x2, next MM's are: 1 at .075, 1@.095, 2@.12
True, might have to wait...w/o volume, can't sell : )
Well after reading that article that deadjim posted i'm hoping that we'll here something on that in the next month or so...we'll see i guess..
An update would be out of the question, apparently the company doesn't care at all about updating shareholders. Volume would be nice to wake it up!!!
Me too...this thing is slow right now but if we could get an update from the company and/or volume this will still move nicely IMO...
Nice find deadjim!
Would love to see a PR about a decision in Benda's favor...:)
Gendicine in a patent war
New to me! Apparantly the ruling is expected soon, and if this chart has upside, this may be the catalyst we're needing.
Good luck
http://www.rsc.org/chemistryworld/Issues/2009/October/GeneTherapyInPatentWars.asp
2006 TIMAasia article
http://www.time.com/time/asia/covers/501061030/profiles.html
Groundbreakers
From biotech to nanotech, three Chinese pioneers look to lead the nation to a new scientific frontier
By Hannah Beech | Shenyang
Posted Monday, October 23, 2006; 20:00 HKT
Nowhere is Asia's scientific revolution unfolding more dramatically than in China, where researchers are taking advantage of bounteous funds and pushing hard to fulfill a government mandate to innovate. Here are three Chinese scientists whose discoveries in the emerging biotech and nanotech fields could transform the way we live and help secure China's position as a scientific superpower:
PENG ZHAOHUI
Gene Healing
In 1998, Chinese molecular biologist Peng Zhaohui left the safe confines of San Diego, where he had worked for several years, for a newly built science park in the southern Chinese boomtown of Shenzhen. His immodest goal: to create a gene-therapy medication that would save many lives. Five years and $6.25 million in government seed money later, the firm Peng founded, Shenzhen SiBiono GeneTech Co., became the first corporation in the world to be granted a license for a gene-therapy treatment. Called Gendicine, the drug aims to combat different types of cancer by injecting a virus laced with a tumor-suppressing gene into the human body. By the end of 2005, more than 3,500 Chinese and foreign patients had been treated for 43 types of cancer with the $1,700-per-dose treatment. (A course typically requires at least six doses.) Peng says that combining radiation and chemotherapy with Gendicine is three times more effective than just using the traditional cancer treatments. "Westerners never imagined that the world's first gene-therapy medication would come from China," he says. "But if they had been watching what was happening in China, they might not have been so surprised."
Gendicine's success is due in part to China's relatively relaxed regulatory environment. American biotech firm Introgen, which has developed rival technology to that used by SiBiono, is still awaiting regulatory approval in the U.S. after undergoing exhaustive clinical trials for its gene-therapy drug. Testing can easily take a decade in the U.S., but SiBiono accomplished it in just six years. Moreover, the trials cost SiBiono just $2,500 per patient, compared to around $100,000 per person in America. The possibly looser rules and comparative lack of transparency surrounding Gendicine's approval by the Chinese Food and Drug Administration have prompted criticism that SiBiono may not have adequately tested the long-term effects of its treatment. Peng's efficacy claims have not been internationally verified but he insists that tests have confirmed the drug is safe and effective. Meanwhile, enthusiasm for gene therapy has chilled somewhat in the U.S., after a patient died during clinical trials of another gene-therapy drug in 1999. Still, Peng is hopeful that Gendicine's licensing will help catapult China into the top ranks of this emerging field. Already, the country's gene-therapy guidelines are being used as a model by other nations publishing their own quality-control regulations. "If SiBiono helps China become a leader in biopharma," says Peng, "I will be quite proud."
CHIEN-MIN CHUNG / GETTY IMAGES FOR TIME
CUTTING EDGE: Lu's work extends the life of high-tech metal tools
LU KE
Metal Man
The unprepossessing clump of buildings that make up the government-run Institute of Metal Research in the grim northeastern city of Shenyang hardly looks like the birthplace of groundbreaking science. But inside its dingy halls, Lu Ke, the institute's 41-year-old director, is doing something truly cutting edge. Lu studies metals on a nano scale—one nanometer equals one millionth of a millimeter. Beginning in 2000, he successfully manipulated the atomic structure of copper to create a pliable material that's as strong as steel yet still maintains its original electrical conductivity. Lu's various types of nanometal can add years to the life of high-tech tools and processors. China's largest steel producer, Baosteel, for instance, has affixed a layer of his nanometal to the surface of the rollers it uses to produce steel sheets, thereby greatly extending the tools' longevity.
Just a decade ago, China wasn't a player in nanotech. But in the 1990s, the country unveiled a national science strategy targeting young fields that could be mined for high-profile innovations. The government's $160 million nanotech drive has freed Chinese researchers like Lu from wasting time scrounging for funds. "It's like China's success with Ping-Pong," says Lu, who this year became the first mainland Chinese to be invited to serve as a review editor for the prestigious Washington, D.C.-based Science journal. "When China decides to focus on something, it can achieve success very quickly."
Born in a mountainous village in China's remote west, Lu was one of only three kids from his high school ever to attend college. He later studied in Germany and the U.S., but his sense of obligation led him back to China. Still, he's not yet satisfied with the state of science in his homeland. "We have to give up the existing system based on seniority and reward people with the most talent," he says. "Science requires shaking things up, but people in China are scared of risk." Of course, this call to shake things up comes from a man who has made a life of busting up atoms. "I like disorder," Lu admits. "It's what excites me."
DAVID HARTUNG FOR TIME
THINK SMALL: Shi's tiny ceramic spheres can boost drugs' efficacy
SHI JIANLIN
Targeted Therapy
Sometimes what's in a drug is not as important as what's around it. Orally administered pills typically release one high-concentration jolt that stays in the system for only 10 hours. But a 200-nanometer carrier (equivalent to one-thousandth the width of a human hair) developed last year by Shi Jianlin, a senior researcher at the Institute of Ceramics in Shanghai, may radically change the way we medicate ourselves. Shi, 43, has created microscopic ceramic spheres that can be loaded with drugs and injected into the bloodstream to slowly release over a 50-hour period. Not only do Shi's mini-drug vehicles offer patients a nifty time-release mechanism, they can also target specific parts of the body. The carriers are outfitted with a magnetic particle, so by putting, say, your hand in a magnetic field, the nanovehicles will move directly there and then unload their cache of drugs. Such specific targeting may lower side effects by keeping medication away from parts of the body that adversely react to a drug. "The idea was pretty simple," says Shi. "But getting it to actually work took a lot of work and luck."
So far, Shi's nanocarriers are too costly for mass use, but it isn't his job to bring the price down. That's the domain of a commercial company, and Shi frets that even as the quality of basic research increases in China, the country could lose out because there are not enough domestic firms to convert innovative technology into commercially viable products. Indeed, science may be the one field in which China is still struggling to live up to its reputation as an unsurpassed manufacturer of low-cost goods. For a man who, with the exception of a year's study in Stuttgart, has stayed in China to conduct his research, the disconnect between idea and commercial application is worrisome. "I hope a Chinese firm can do something with our idea," he says. "It would be a pity if we invent something and someone else took advantage of it."
With reporting by Bu Hua/Shanghai
We'll see who's right on Monday.
I still am under the impression that one
buyer bought all the shares that were priced
0.07 and less.
The price and number of shares bought are
48,744 shares @ 0.0569
Don't forget, this was a buy !
The price, 0.0569 per share seems to me
a very likely average when buying all 0.04s
to 0.07s included.
IMO there is a good chance we see this open
on Monday at 0.07+
GLTY !
John
There is a larger holder selling...IMO this trade represents the shares that were sold today by this seller and the MMs settled it AH.
Just my opinion.
GLTY.
Thanks, green next week sounds good to me!!
Have a good weekend also!
~J
48,744 shares traded @ 0.0569 --4:38 PM
As you can see J-Dawg, somebody all of a sudden got an appetite for BPMA.
My feeling is that this person has been waiting all day to get filled at 0.04, but at the end had to settle for 0.0569 and if that's the case we should see green again Monday.
Have a good weekend and GLTA !
John
BPMA --- green days ahead IMO
GLTA
John
My etrade marketcaster currently shoes:
bid @.02
ask @.12
close @ .075
Will just have to wait to see how it's sorted out later....
~J
This is what Questrader is showing me;
Price Size Exch Time
t 0.06 500 OBB 16:01:42
0.075 500 OBB 15:59:42
So I'd say we closed @ 0.06
Have a good weekend !
John
Did we close at 075 or 4 or 6...my etrade is saying 3 different things.
Yea i think so too...I'm no pro at charts but this does look like it is going to bounce from here....JMO of course..
Normal trading action this will pop!!!!eom
tell me about it....people just can't stop whacking this one..oh well if it goes back to .025, i'm just gonna buy more i guess...:)
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
643
|
Created
|
08/26/07
|
Type
|
Free
|
Moderators |
On May 21, Benda Pharma (BPMA.OB) reported revenue of $3 million for Q1 of 2007, a decrease of 17% from the year-earlier period. Benda blamed the decrease on a temporary closing of its bulk chemical plant, a closing undertaken at the behest of the Chinese government, which mandated a cleanup of the wastewater of the plant. The plant is scheduled to be back online in August of this year.
Net income dropped to $0.4 million for the quarter, a decline of 51%. Besides the plant closing, Benda said it encountered additional expenses associated with being a public company. Benda has 96.3 million shares outstanding and, at its current price of $1.70 per share, it has a market capitalization of $164 million.
Benda is involved in making western and Traditional Chinese Medications, and it manufactures active pharmaceutical ingredients.
Quote:
http://www.bendapharma.com/stockquote.cfm
http://www.stockcharts.com/c-sc/sc?s=BPMA&p=D&yr=0&mn=5&dy=0&i=p68304234748&r=6802
In April of 2007, Benda bought a 57.57% ownership in Shenzhen SiBiona, which produces the cancer drug Gendicine, the first gene therapy medication for cancer available anywhere in the world. In 2004, Gendicine was approved by Chinese officials for use against head and neck cancer, which is also known as squamous cell cancer. The drug is injected once per week for eight weeks. In the Chinese trials, it achieved a complete remission in 64% of the cases and a partial remission in 32% of the patients. Gendicine was originally priced at $362 per injection.
To buy the stake in SiBiono, Benda paid $7.7 million and gave SiBiono 2.1 million shares of Benda stock in return for financial consulting services. Benda also guaranteed that its shares would be worth $3.60 per share within three months after the expiration of the 12-month restriction on selling the shares.
Benda operates three plants in the Hubei Province of China: Benda Ebei, which produces conventional medicines and Traditional Chinese Medicines; Jiangling Benda, which produces active pharmaceutical; and Yidu Benda, which produces bulk chemicals.
INSTITUTIONAL OWNERSHIP
Pope Investments LLC owns 22,337,998 shares accounting for 21.24% of shares outstanding!!
pinksheets.com/edgar/GetFilingHtml
SHARE STRUCTURE
As of August 19, 2009:
Shares Outstanding:105,155,355
Shares Authorized:150,000,000
[img]stockcharts.com/c-sc/sc?s=bpma&p=d&b=5&g=0&id=p86819233489[/img]
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |